This is a working overview of nasal drops, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-09 and is reviewed periodically as new material appears.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
It is capable of assuming more than one conformation. At least one of the conformations creates a channel through the membrane that is permeable to specific types of ions. The transition between conformations is influenced by the membrane potential. Thus, a voltage-gated ion channel tends to be open for some values of the membrane potential, and closed for others. In most cases, however, the relationship between membrane potential and channel state is probabilistic and involves a time delay. Ion channels switch between conformations at unpredictable times: The membrane potential determines the rate of transitions and the probability per unit time of each type of transition.
=== Homologues === Each domain of life (Eubacteria, Archaea, and Eukaryotes) have different release factors associated with the termination of translation. Eubacteria have multiple release factor to recognize stop codons whereas Eukaryotes (eRF1) and Archaea (aRF1) have only one protein to recognize all three stop codons. The structural and functional differences between Eubacteria release factors and Archean/Eukaryotic are believed to have evolved separately with a divergence point early on. The functional similarities between eRF1 and aRF1 has led to theories of a common ancestor where both proteins evolved from. However, very little has been studied about Archean release factors. In prokaryotes, the release factors are characterized in 2 classes. Class 1 release factors recognize stop codon, and class 2 release factors stimulate hydrolysis by GTPase activity. However, prokaryotes don't have a single protein to recognize all the stop codons. The stop codon UAG is decoded by Release Factor 1 (RF1) and UGA is decoded by Release Factor 2. The final stop codon UAA is decoded by both RF1 and RF2. In Eukaryotes, eRF1 recognizes all three stop codons. Although there is a distinct difference between prokaryotic codon recognition and Archean/Eukaryotic codon recognition, the functionality of the catalytic site is conserved throughout all domains. Each domain has the critical GGQ site to promote peptide hydrolysis.
Barry Windsor-Smith, who had come to prominence illustrating Marvel's Conan the Barbarian series, collaborated with Claremont for the "Wounded Wolf" story that was published as Uncanny X-Men #205 (May 1986), focusing entirely on Wolverine. The story introduced a new adversary for Wolverine, Lady Deathstrike. The "Mutant Massacre" story arc of 1986 brought Sabretooth into conflict with the X-Men and particularly Wolverine. Byrne had previously designed Sabretooth as an enemy of the martial artist superhero Iron Fist in Iron Fist #14 (August 1977), written by Claremont. Sabretooth's face was based on a preliminary and unused drawing Byrne had proposed for Wolverine; he became Wolverine's archenemy. Marvel launched an ongoing Wolverine title written by Claremont with art by John Buscema in November 1988. In the late 1980s, Wolverine featured in self-contained crossover stories with two other characters: Spider-Man, in Spider-Man versus Wolverine (1987), by Christopher Priest and M.D. Bright, and Nick Fury, in Wolverine/Nick Fury: The Scorpio Connection (1989), written by Archie Goodwin with art by Howard Chaykin.
=== Seizures === Phenobarbital is used in the treatment of all types of seizures, except absence seizures. It is no less effective at seizure control than phenytoin, but phenobarbital is not as well tolerated. Phenobarbital may provide a clinical advantage over carbamazepine for treating partial seizures. Carbamazepine may provide a clinical advantage over phenobarbital for generalized tonic–clonic seizures. The first-line drugs for treatment of status epilepticus are benzodiazepines, such as lorazepam, clonazepam, midazolam, or diazepam. If these fail, then phenytoin may be used, with phenobarbital being an alternative in the US (favored in infants), but used only third-line in the UK. Failing that, the only treatment is anesthesia in intensive care. The World Health Organization (WHO) gives phenobarbital a first-line recommendation in the developing world and it is commonly used there. Phenobarbital is the first-line choice for the treatment of neonatal seizures. Concerns that neonatal seizures in themselves could be harmful make most physicians treat them aggressively. However, no reliable evidence supports this approach.
=== Weaning === Weaning is the process of replacing breast milk with other foods; the infant is fully weaned after the replacement is complete. Psychological factors affect the weaning process for both mother and infant, as issues of closeness and separation are very prominent. Unless a medical emergency necessitates abruptly stopping breastfeeding, it is best to gradually increase the period between feedings or eliminate feedings to allow the breasts to adjust to the decreased demands without becoming engorged. Studies show that a large number of women discontinue breastfeeding early due to lack of working place support for breastfeeding mothers. La Leche League advises parents to shift their children's focus at bedtime away from breastfeeding, as it is often the most difficult feeding for them to let go. If weaning starts at 12 months or later, it is not necessary to switch to infant formula or "toddler formula" as is sold commercially. At 12 months, it is recommended that the baby be switched to whole cow's milk. Reduced-fat or skim milk generally is not appropriate before age 2 because it lacks sufficient fat or calories to promote early brain development. If the mother was experiencing lactational amenorrhea, periods will begin to return with weaning, along with restored fertility.
Sources: en.wikipedia.org
GABA, also known as gamma-aminobutyric acid or γ-aminobutyric acid, is the chief inhibitory neurotransmitter in the developmentally mature mammalian central nervous system. Its principal role is reducing neuronal excitability throughout the nervous system. GABA is sold as a dietary supplement in many countries. It has been traditionally thought that exogenous GABA (i.e., taken as a supplement) does not cross the blood–brain barrier, but data obtained from more recent research (2010s) in rats describes the notion as being unclear. The carboxylate form of GABA is γ-aminobutyrate.
Protein combining was historically promoted as a method of compensating for protein deficiencies in most vegetables as foods, found in limiting percentages revealed in their respective amino acid profiles. In this dogma of the 1970s, each meal needed to be combined to form complete proteins. Though it is undisputed that diverse foods can be thoughtfully combined to make a more nutritious meal, studies on essential amino acid contents in plant proteins have shown that careful combination in each individual meal is not at all required for vegetarians and vegans to reach the desired level of essential amino acids as long as their diets are varied and daily caloric requirements are met. In other words, combination can happen over a longer course of time.
(Note: If the fluid in question is seawater, it will not have the same density (ρ) at every location. For this reason, a ship may display a Plimsoll line.) It can be the case that forces other than just buoyancy and gravity come into play. This is the case if the object is restrained or if the object sinks to the solid floor. An object which tends to float requires a tension restraint force T in order to remain fully submerged. An object which tends to sink will eventually have a normal force of constraint N exerted upon it by the solid floor. The constraint force can be tension in a spring scale measuring its weight in the fluid, and is how apparent weight is defined. If the object would otherwise float, the tension to restrain it fully submerged is:
Ac-SDKP (Thymosin Beta 4 Fragment (1–4), Goralatide) is an endogenous tetrapeptide derivative that is the N-acetylated derivative of the fragment composed of amino acids 1-4 derived from cleavage of the N-terminus of the signalling factor thymosin beta-4 by the enzyme prolyl oligopeptidase. It is a selective inhibitor of haematopoietic cell proliferation and has antiinflammatory, anti-fibrotic, and pro-angiogenic properties, with particular applications in preventing the development of kidney fibrosis and cardiac fibrosis following injury to these organs.
=== Medicine storage and usage by astronauts === Medication storage and on-site production have become crucial areas of research due to extensive periods away from Earth. Factors, such as shelf life and drug stability, on drug storage, are impacted due to the effects of radiation, long space flight durations, and microgravity. Current solutions aim at frequent missions to resupply and restock medicines and commonly used drugs, however, this is not possible for long-term spaceflight to Mars or other distant missions. In addition, due to the toll that spaceflight takes on the human body, medicine use by astronauts have been extensively studied. High rates of sleep medication are taken by astronauts to combat sleep deprivation, disturbances, and other sleep-related disorders caused by an increased presence of CO2 in the International Space Station. Medications for congestion and allergies, combined with headache-related medications, are also significantly used, primarily because of the cephalad fluid shifts caused by a transition to weightless environment.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.